LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

1.63 0.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.6099999999999999

Max

1.63

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.8M -16M
Verkoop	-8.7M 5.5M
Winstmarge	-282.723
Werknemers	81
EBITDA	-4.2M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+132.12% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	43M 695M
Vorige openingsprijs	1.01
Vorige sluitingsprijs	1.63

Nieuwssentiment

By Acuity

50%

153 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

0.6863 / 0.72 Steun & Weerstand

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29 mrt 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls Amid Rising Inflation Fears -- Market Talk

29 mrt 2026, 23:46 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29 mrt 2026, 23:35 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29 mrt 2026, 23:23 UTC

Marktinformatie

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29 mrt 2026, 22:34 UTC

Marktinformatie

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29 mrt 2026, 22:09 UTC

Marktinformatie

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29 mrt 2026, 21:06 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29 mrt 2026, 21:03 UTC

Marktinformatie

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29 mrt 2026, 21:01 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29 mrt 2026, 09:30 UTC

Acquisities, Fusies, Overnames

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28 mrt 2026, 08:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

132.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.83 USD 132.12%

Hoogste 6 USD

Laagste 1 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Lexicon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.6863 / 0.72Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

153 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.